
CLAIMS

1. A compound of general formula (I):



(I)

wherein

R^1 represents substituted or unsubstituted, aromatic or non-aromatic heterocyclyl; substituted or unsubstituted aryl; or substituted or unsubstituted cycloalkyl;

R^2 ~~and R^3, identical or different,~~ represents a hydrogen atom; F; Cl; Br; I; CF_3; OH; SH; ~~NH_2;~~ CN; substituted or unsubstituted ~~alkyl~~methyl; substituted or unsubstituted alkenyl; substituted or unsubstituted alkoxy; substituted or unsubstituted cycloalkyl; ~~substituted or unsubstituted aryl;~~ substituted or unsubstituted, ~~aromatic or~~ non-aromatic heterocyclyl; substituted or unsubstituted cycloalkylalkyl; substituted or unsubstituted arylalkyl; substituted or unsubstituted, aromatic or non-aromatic heterocyclylalkyl; a (C=O)-R^7 group; a (C=O)-O-R^8 group; a S(O)$_t$-R^9 group; or a (C=O)-NR^{10}R^{11} group;

R^3 represents a hydrogen atom; F; Cl; Br; I; CF_3; OH; SH; NH_2; CN; substituted or unsubstituted alkyl; substituted or unsubstituted alkenyl; substituted or unsubstituted alkoxy; substituted or unsubstituted cycloalkyl; substituted or unsubstituted aryl; substituted or unsubstituted, aromatic or non-aromatic heterocyclyl; substituted or unsubstituted cycloalkylalkyl; substituted or unsubstituted arylalkyl; substituted or unsubstituted, aromatic or non-aromatic

heterocyclylalkyl; a (C=O)-R^7 group; a (C=O)-O-R^8 group; a S(O)$_t$-R^9 group; or a (C=O)-$NR^{10}R^{11}$ group;

$\mathbf{R^4}$ and $\mathbf{R^5}$, identical or different, represent a hydrogen atom; substituted or unsubstituted alkyl; substituted or unsubstituted alkenyl; substituted or unsubstituted alkoxy; substituted or unsubstituted cycloalkyl; substituted or unsubstituted aryl; substituted or unsubstituted, aromatic or non-aromatic heterocyclyl; substituted or unsubstituted cycloalkylalkyl; substituted or unsubstituted arylalkyl; substituted or unsubstituted, aromatic or non-aromatic

heterocyclylalkyl; a (C=O)-R^7 group; a (C=O)-O-R^8 group; a $S(O)_t$-R^9 group; or a (C=O)-$NR^{10}R^{11}$ group;

or

together form, with the nitrogen atom to which they are attached, a substituted or unsubstituted, aromatic or non-aromatic heterocyclyl group;

X represents an oxygen atom or a CH-R^{12} group wherein R^{12} is selected from H, CH_3, SH, OH, NH_2, CF_3, Cl, F, Br, I, and CN;

m is selected from 1, 2, 3 and 4;


n is selected from 1, 2, 3 and 4;

t is selected from 1, 2 and 3;

R^7, **R^8**, **R^9**, **R^{10}** and **R^{11}**, identical or different, represent a hydrogen atom; substituted or unsubstituted C_{1-6} alkyl; substituted or unsubstituted C_{2-6} alkenyl; substituted or unsubstituted C_{1-6} alkoxy; substituted or unsubstituted cycloalkyl; substituted or unsubstituted aryl; substituted or unsubstituted, aromatic or non-aromatic heterocyclyl; substituted or unsubstituted cycloalkylalkyl; substituted or unsubstituted arylalkyl; substituted or unsubstituted, aromatic or non-aromatic heterocyclylalkyl;

or a pharmaceutically acceptable salt, ~~isomer~~enantiomer, diastereoisomer~~, prodrug~~ or solvate thereof;

with the proviso that the compound of general formula (I) is not



2. The compound according to claim 1, wherein R^1 is selected from a 5-to 10 membered substituted or unsubstituted, aromatic or non-aromatic heterocyclyl group ~~which preferably contains N, O or S as ring member~~; a 5-to 10 membered substituted or unsubstituted aryl group; and a 5-to 10 membered substituted or unsubstituted cycloalkyl group.

3. The compound according to claim 2, wherein the 5-to 10 membered substituted or unsubstituted, aromatic or non-aromatic heterocyclyl group is selected from a 5-to 10 membered substituted or unsubstituted, aromatic or non-aromatic heterocyclyl group which contains N, O or S as ring member.

~~3~~4. The compound according to claim 2, wherein R^1 is selected from substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl, substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted thiophene, substituted or unsubstituted benzothiophene, substituted or unsubstituted benzofuran, substituted or unsubstituted pyridine and substituted or unsubstituted quinoline.

~~4~~5. The compound according to claim ~~3~~4, wherein R^1 is selected from the group consisting of: 2-thienyl, 3-thienyl, 2,5-dichloro-3-thienyl, 2,3-dichloro-5-thienyl, 2,3-

dichloro-4-thienyl, 2-benzothienyl, 3-benzothienyl, 4-benzothienyl, 5-benzothienyl, 7-benzothienyl, 2-benzofuryl, 5-benzofuryl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-quinolyl, 3-quinolyl, 5-quinolyl, 6-quinolyl, 3,4-difluorophenyl, 3,4-dichlorophenyl, cyclopentyl, cyclohexyl, 7-hydroxy-2-naphthyl, 6-hydroxy-2-naphthyl, 5-hydroxy-2-naphthyl, 6-fluoro-2-naphthyl, 6-methoxy-2-naphthyl, 6-bromo-2-naphthyl, 6-hidroxymethyl-2-naphthyl, 6-fluromethyl-2-naphthyl, 7-hydroxy-1-naphthyl, 6-hydroxy-1-naphthyl, 5-hydroxy-1-naphthyl, 5-fluoro-1-naphthyl, 5-bromo-1-naphthyl and 1-naphthyl.

~~5~~6. The compound according to any of the preceding claims, wherein R^2 ~~and R^3 are independently~~is selected from H and ~~substituted or unsubstituted C_{1-6} alkyl group, preferably~~ methyl.

7. The compound according to any of the preceding claims, wherein R^3 is selected from H and substituted or unsubstituted C_{1-6} alkyl group.

8. The compound according to claim 7, wherein R^3 is selected from H and methyl.

~~6~~9. The compound according to any of claims ~~5~~6-8, wherein R^2 is methyl and R^3 is H, or R^2 and R^3 are simultaneously H or methyl.

~~7~~10. The compound according to any of the preceding claims, wherein R^4 and R^5 form together with the nitrogen atom to which they are attached a substituted or unsubstituted heterocyclyl group.

~~8~~11. The compound according to claim ~~7~~10, wherein R^4 and R^5 form together a morpholine-4-yl group, a piperidine group, pyrrolidine group or a piperazine-4-yl group.

~~9~~12. The compound according to any of the preceding claims, wherein each m and n independently represent 1 or 2.


~~10~~13. A compound according to any of the preceding claims selected from the group consisting of:

4-(2-((1-(3,4-dichlorophenyl)-5-methyl-1*H*-pyrazol-3-yl)methoxy)ethyl)morpholine,
4-(2-((5-methyl-1-(naphthalen-2-yl)-1*H*-pyrazol-3-yl)methoxy)ethyl)morpholine,
4-(3-(1-(3,4-dichlorophenyl)-5-methyl-1*H*-pyrazol-3-yl)propyl)morpholine,
4-(3-(5-methyl-1-(naphthalen-2-yl)-1*H*-pyrazol-3-yl)propyl)morpholine,
4-(2-(2-(1-(3,4-dichlorophenyl)-5-methyl-1*H*-pyrazol-3-yl)ethoxy)ethyl)morpholine,
4-(2-((1-cyclohexyl-5-methyl-1H-pyrazol-3-yl)methoxy)ethyl)morpholine,
4-(3-(1-cyclohexyl-5-methyl-1H-pyrazol-3-yl)propyl)morpholine,
1-(3,4-dichlorophenyl)-5-methyl-3-((2-(pyrrolidin-1-yl)ethoxy)methyl)-1H-pyrazole,
1-(2-((1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yl)methoxy)ethyl)piperidine,
1-(4-(2-((1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone,
(2S,6R)-4-(2-((1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yl)methoxy)ethyl)-2,6-dimethylmorpholine,

1-(4-(2-((1-(3,4-difluorophenyl)-5-methyl-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone,
1-(4-(2-((1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone,
4-(2-((1-(3,4-difluorophenyl)-5-methyl-1H-pyrazol-3-yl)methoxy)ethyl)morpholine,
4-(2-((1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)methoxy)ethyl)morpholine,
4-(3-((1-(3,4-difluorophenyl)-5-methyl-1H-pyrazol-3-yl)methoxy)propyl)morpholine,
1-(4-(2-((1-cyclohexyl-5-methyl-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)propan-1-one,
1-(4-(2-((1-cyclohexyl-5-methyl-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)-2-methylpropan-1-one,
1-(4-(2-((1-cyclohexyl-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)propan-1-one,
1-(4-(2-((1-cyclohexyl-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)-2-methylpropan-1-one,
1-(4-(2-((1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)propan-1-one,
1-(4-(2-((1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)-2-methylpropan-1-one,
1-(4-(2-((1-(3,4-dichlorophenyl)-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)propan-1-one,
1-(4-(2-((1-(3,4-dichlorophenyl)-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)-2-methylpropan-1-one,
or a pharmaceutically acceptable salt~~, prodrug~~ or solvate thereof.

~~11~~14. A process for the preparation of a compound of formula (I) as defined in any of claims 1 to ~~10~~13, or a salt, enantiomer, diastereoisomer~~isomer~~ or solvate thereof, which is selected from one of the following:

a) a process which comprises the reaction of a compound of formula (II)



(II)

in which R_1, R_2 and R_3 are as defined in claim 1, with a compound of formula (III)

~~12~~15. A medicament comprising at least one compound of formula (I) as defined in any of claims 1 to ~~10~~13, or a pharmaceutically acceptable salt, enantiomer, diastereoisomer~~isomer~~, ~~prodrug~~ or solvate thereof and a pharmaceutically acceptable excipient.

~~13~~16.~~-~~ Compound of formula (I) as defined in any of claims 1 to ~~10~~ 13 for use as a medicament.

~~14~~17. ~~Compound according to claim 13, wherein the~~Use of a compound as defined in any of claims 1 to 13 in the manufacture of a medicament ~~is~~ for the treatment and/or prophylaxis of a sigma receptor-mediated disease or condition.

~~15~~18. ~~Compound~~ Use according to claim ~~14~~17, wherein the disease comprises diarrhea; lipoprotein disorders; migraine; obesity; elevated triglyceride levels; chylomicronemia; dysbetalipoproteinemia; hyperlipoproteinemia; hyperlipidemia; mixed hyperlipidemia; hypercholesterolemia; hypertriglyceridemia; sporadic hypertriglyceridemia; inherited hypertriglyceridemia; dysbetalipoproteinemia; arthritis; hypertension; arrhythmia; ulcer; learning, memory and attention deficits; cognition disorders; neurodegenerative diseases; demyelinating diseases; addiction to drugs and chemical substances including cocaine, amphetamine, ethanol and nicotine; tardive dyskinesia; ischemic stroke; epilepsy; stroke; stress; cancer; psychotic conditions~~, in particular depression, anxiety or schizophrenia~~; inflammation; and autoimmune diseases.

19. Use according to claim 18, wherein the psychotic condition is depression, anxiety or schizophrenia.

~~16~~20. ~~Compound~~ Use according to claim ~~14~~17, wherein the disease comprises pain~~, preferably neuropathic pain, inflammatory pain or other pain conditions involving allodynia and/or hyperalgesia~~.

21. Use according to claim 20, wherein the pain is neuropathic pain, inflammatory pain or other pain conditions involving allodynia and/or hyperalgesia.

~~17~~22. Compound of general formula (I) as defined in any of claims 1 to ~~10~~ 13 for use as a pharmacological tool.